Houston-born Matt Mullenweg joined the Greater Houston Partnership for a fireside chat on his tech company Automattic's success of distributed work. Photo via ma.tt

The pandemic and the measures companies have taken to prevent the spread of COVID-19 have opened employers eyes to non-traditional ways of working. An increased percentage of the workforce pivoted to remote working this year — in some cases, this was the first time employees were allowed to work from home.

But not having a traditional office setup is far from new to Houston native Matt Mullenweg, founder of WordPress. He started his company with remote team members basically from day one. In a virtual fireside chat with Scott McClelland, president of H-E-B Food & Drug, for Greater Houston Partnership's Houston NEXT: An ERG Summit last month, Mullenweg describes why he feels confident that a remote — or distributed, has he defines it — workforce is the future.

"Words are really important, and when I hear the word 'remote,' I think there's a central office and then there's someone who's not part of it," Mullenweg says during the chat. "So, we were trying to think of something that captured the fact that we were close to each other in our work — we're just not physically in the same place most of the time. 'Distributed' is what we came up with."

For Mullenweg, this way of running his business was advantageous for the company at its founding in 2000. Since those early days, Automattic, WordPress's parent company, has raised around $700 million in venture funding and made around 20 acquisitions. This success, Mullenweg says, is in part due to distributed work.

"All of this is designed to create a really robust network so that the work can continue regardless of location or anything," Mullenweg says on his workforce structure. "This especially during the early days, allowed us to work two or three times faster than our competitors because when they were doing five days of work a week, we were doing 15 days of work a week."

Mullenweg's plan for distributed work has been the subject a series of blogs, a podcast, and even a TED Talk. As passionate as he is that it is the future of the workforce, he realizes there's a process to getting there, and it's going to take time. He explains a five-tiered process that focuses on strategic culture changes and tech optimization.

"I think you need to have a culture and a way of working that allows people who aren't physical co-present with their colleagues to be productive," Mullenweg says. "The truth is not every company is there yet."

While Mullenweg always believed the rise of distributed work would reach milestones throughout his lifetime, the pandemic might be accelerating crucial steps toward the growth of this type of workforce. Especially since, as Mullenweg explains, this isn't the last major event that's going to occur and prevent in-person work.

"We're all hoping COVID to be gone as soon as possible, but this isn't the last thing like this. I'm sure there are going to be other issues that require us to be more decentralized in the future," Mullenweg says. "If you can get good at that as an organization, you'll be primed to succeed in the coming decades as a business."

Ultimately, distributed work has a lot of potential in the modern workforce, and the structure can do wonders for business advancement as well as employee moral.

"One thing we've found is that when people are really happy and fulfilled, they bring their best selves to work — they're more creative and have more energy," Mullenweg says.

Houston NEXT: An ERG Summit - Fireside Chat with Matt Mullenwegwww.youtube.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”